Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance Study
Gert Van Assche(KU Leuven), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Philippe Szapary(Cedars-Sinai Medical Center), LW Rupert(Macquarie University), BE Sands(Icahn School of Medicine at Mount Sinai), Ş. Targan(Cedars-Sinai Medical Center), Thomas Baker(Janssen (United States)), CD O'Brien(Janssen (United States)), H Zhang(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Tadakazu Hisamatsu(Kyorin University)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k